Vascepa

Amarin Corporation plc (NASDAQ: AMRN) shares were plummeting on above-average volume as an appeal hearing on the Vascepa fish oil capsule patent gets underway.  What Happened: Amarin appealed against a late March ruling that its Vascepa patents were invalid. The invalidation of the patents...

Amarin Corporation plc (NASDAQ: AMRN) shares were advancing strongly Tuesday following the release Tuesday of second-quarter results. What Happened: Amarin reported second-quarter revenue of $135.3 million, up 34% year-over-year, but below the $149.48-million consensus estimate. "...

Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa.  The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price...

Amarin Corporation plc (NASDAQ: AMRN) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a third-party pilot trial of its Vascepa in COVID-19, were giving back the gains Friday.  First Vascepa Generic Greenlighted The negative sentiment...

Amarin Corporation plc (NASDAQ: AMRN) shares were tumbling Tuesday in reaction to a negative verdict issued by a U.S. District Court regarding generic versions of its fish oil pill Vascepa. Amarin shares, which rose to 52-week high of $26.12 in mid-December in reaction to a Vascepa...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 30.) Athersys Inc (NASDAQ: ATHX) (reacted to $7-million capital injection by Japanese partner) Quidel Corporation (NASDAQ: QDEL) Down In The Dumps (...

The shares of Amarin Corporation plc (NASDAQ: AMRN) tanked in the after-hours session on Monday as the court ruled against its patent for heart treatment drug Vascepa. What Happened The United States District Court for the District of Nevada in Las Vegas ruled that six patents on Vascepa,...

Benzinga's PreMarket Prep airs every morning from 8-9:00 a.m. EST. During that fast-paced highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given day, the...

Christmas came early for Amarin Corporation plc (NASDAQ: AMRN) with the FDA's approval of an expanded label for its fish oil pill Vascepa ahead of a scheduled Dec. 28 decision date.  The label expansion approved Friday includes the indication of cardiovascular risk reduction in...

Amarin Corporation (NASDAQ: AMRN) traded higher after the FDA's Endocrinologic and Metabolic Drug Advisory Committee voted 16-0 to recommend approval of label expansion for Vascepa capsules to include reduction in the risk of cardiovascular, or CV, events in high-risk patients. Vascepa is the...

Amarin Corporation plc (NASDAQ: AMRN) shares were halted for trading Thursday morning pending an announcement of the Adcom verdict on the label expansion it is seeking for its fish oil pill Vascepa. Amarin shares have been on a tear this week, with the stock gaining about 24% Tuesday in...

Amarin Corporation plc (NASDAQ: AMRN) shares were climbing to a 3-1/2 month high Tuesday after the FDA posted a briefing document ahead of an Adcom meeting on Amarin's fish oil capsule Vascepa that's scheduled for Thursday. Vascepa, or icosapent ethyl, was previously...

Shares of the mid-cap biotech Amarin Corporation plc (NASDAQ: AMRN) were pulling back to their lowest level since early January on Friday. What Happened Amarin said Thursday after the market close that it was notified by the FDA of the agency's intention to hold an Adcom meeting for...

Shares of mid-cap biotech Amarin Corporation plc (NASDAQ: AMRN) are advancing solidly in pre-market trading Wednesday. What Happened Amarin said Wednesday that its sNDA for Vascepa capsules — icosapent ethyl capsules, or a fish oil pill — has been accepted by...

Amarin Corporation plc (NASDAQ: AMRN) shares have been on a strong upward trend since late Wednesday, with the buying momentum continuing into Thursday's session. What Happened Amarin's stock was reacting to a release from the American Diabetes Association, or ADA, that includes Amarin...